ReCode Therapeutics is dedicated to advancing genetic medicine with their innovative Selective Organ Targeting (SORT) lipid nanoparticle technology, designed to enhance delivery to specific organs and cells. This precise focus not only fulfills unmet medical needs in rare diseases but also places the company at the fore of addressing limitations in current gene therapy technologies. With a clear commitment to improving patient outcomes and a robust pipeline featuring redosing capabilities, this organization provides a dynamic and forward-thinking environment for its employees, championing both professional growth and scientific innovation.